These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 23875595)
1. [The yield of tigecycline in the treatment of community-acquired pneumonia]. Cilli A Tuberk Toraks; 2013; 61(2):155-61. PubMed ID: 23875595 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. Tanaseanu C; Milutinovic S; Calistru PI; Strausz J; Zolubas M; Chernyak V; Dartois N; Castaing N; Gandjini H; Cooper CA; BMC Pulm Med; 2009 Sep; 9():44. PubMed ID: 19740418 [TBL] [Abstract][Full Text] [Related]
7. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. Dartois N; Castaing N; Gandjini H; Cooper A; J Chemother; 2008 Oct; 20 Suppl 1():28-35. PubMed ID: 19036672 [TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the efficacy and safety of tigecycline for treatment of respiratory tract infections: systematic review of literature]. Moya Cordero P; Ruiz-Aragón J; Molina Linde JM; Márquez-Peláez S; Motiva Sánchez V Rev Chilena Infectol; 2013 Dec; 30(6):591-7. PubMed ID: 24522299 [TBL] [Abstract][Full Text] [Related]
9. [Tigecycline: a systematic review of clinical experience during first years of prescription]. Diomedi P A Rev Chilena Infectol; 2009 Apr; 26(2):114-25. PubMed ID: 19621142 [TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563 [TBL] [Abstract][Full Text] [Related]
11. Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin. Ramirez JA; Cooper AC; Wiemken T; Gardiner D; Babinchak T; BMC Infect Dis; 2012 Jul; 12():159. PubMed ID: 22812672 [TBL] [Abstract][Full Text] [Related]
12. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae. Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830 [TBL] [Abstract][Full Text] [Related]
13. An update for community-acquired bacterial pneumonia pharmacotherapy: what's new and where does it fit? DeBellis HF; Jones MC; Kincaid SE J Pharm Pract; 2012 Dec; 25(6):569-75. PubMed ID: 23065389 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia. Bradford PA; Petersen PJ; Tuckman M; Jones CH Clin Microbiol Infect; 2008 Sep; 14(9):882-6. PubMed ID: 18844692 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia. Rubino CM; Bhavnani SM; Forrest A; Dukart G; Dartois N; Cooper A; Korth-Bradley J; Ambrose PG Antimicrob Agents Chemother; 2012 Jan; 56(1):130-6. PubMed ID: 21968360 [TBL] [Abstract][Full Text] [Related]